(±)-Forbesione

(±)-Forbesione 是 Forbesione 的消旋体,是一种潜在的细胞凋亡 (apoptosis) 诱导剂,可抑制癌细胞增殖,并可用于癌症的相关研究。
产品编号: MS-W98707 CAS No.: 667914-50-3 分子式: C28H32O6 分子量: 464.55
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

(±)-Forbesione 是 Forbesione 的消旋体,是一种潜在的细胞凋亡 (apoptosis) 诱导剂,可抑制癌细胞增殖,并可用于癌症的相关研究。

生物实验数据

生物活性 (±)-Forbesione, the racemate of Forbesione, is a potential apoptosis inducer that inhibits cancer cell proliferation and can be used in cancer-related research.
体外研究
(In Vitro)

(±)-Forbesione (Compound 32) (24 小时) 对 HepG2、A549 和 U251 细胞表现出低微摩尔级的抗增殖活性,其 IC50 值分别为 4.07 μM、3.58 μM 和 8.57 μM。

Cell Cycle Analysis

Cell Line: Ham-1 cholangiocarcinoma cells
Concentration: 0.5 µM; 1 µM; 2 µM; 4 µM; 8 µM
Incubation Time: 24 h
Result: Induced concentration-dependent S-phase cell cycle arrest (P<0.01).
Reduced the proportion of cells in the G0/G1 (P<0.05) and G2/M (P<0.05) phases.
Increased the percentage of cells in the sub-G1 fraction (apoptotic cells) significantly in a concentration-dependent manner (P<0.01).

Apoptosis Analysis

Cell Line: Ham-1 cholangiocarcinoma cells
Concentration: 2 µM; 4 µM; 8 µM; 16 µM
Incubation Time: 24 h
Result: Induced bright green, condensed, and fragmented chromatin, which are hallmarks of apoptosis, in treated cells, while untreated cells showed uniformly green-stained, normal nuclei.

Apoptosis Analysis

Cell Line: Ham-1 cholangiocarcinoma cells
Concentration: 2 µM; 4 µM; 8 µM; 16 µM; 32 μM
Incubation Time: 6, 24, 48 h
Result: Increased the percentage of apoptotic cells in a concentration- and time-dependent manner.
Resulted in 50.75% (P<0.01), 55.57% (P<0.001), and 64.43% (P<0.001) apoptotic cells at 6, 24, and 48 h respectively when treated with 32 µM.

Western Blot Analysis

Cell Line: Ham-1 cholangiocarcinoma cells
Concentration: 2 µM; 4 µM; 8 µM
Incubation Time: 24 h
Result: Significantly decreased protein expression of cyclin E (P<0.01), cyclin A (P<0.05), and cyclin-dependent kinase 2 (Cdk2) (P<0.01).
Significantly increased protein expression of p21 (P<0.05) and p27 (P<0.05) compared to control cells.\nIncreased protein expression of Fas (P<0.05), Fas-associated death domain (FADD) (P<0.05), and activated caspase-3 (P<0.05) in the death receptor pathway.
Decreased protein expression of procaspase-8 (P<0.05) and procaspase-3 (P<0.01) in the death receptor pathway.
Increased protein expression of B-cell lymphoma-2-like protein 4 (Bax) (P<0.05), activated caspase-9 (P<0.05), and activated caspase-3 (P<0.05) in the mitochondrial pathway.
Decreased protein expression of B-cell lymphoma-2 (Bcl-2) (P<0.05), procaspase-9 (P<0.05), and procaspase-3 (P<0.01) in the mitochondrial pathway.
Increased protein expression of activated caspase-12 (P<0.05), activated caspase-9 (P<0.05), and activated caspase-3 (P<0.05) in the endoplasmic reticulum pathway.
Decreased protein expression of procaspase-12 (P<0.05), procaspase-9 (P<0.05), and procaspase-3 (P<0.01) in the endoplasmic reticulum pathway.\nSignificantly decreased protein expression of NF-κB/p65 (P<0.01) compared to control cells.
Significantly increased protein expression of inhibitor of κB-α (IκB-α) (P<0.05) compared to control cells.\nSignificantly decreased protein expression of cytokeratin 19 (CK19) (P<0.01) compared to control cells.
Significantly decreased protein expression of proliferating cell nuclear antigen (PCNA) (P<0.05) compared to control cells.

Apoptosis Analysis

Cell Line: human cholangiocarcinoma KKU-100 cells
Concentration: 0.25 µM; 0.5 µM; 1 µM; 2 μM; 1 μM (combined with 0.025 μM Doxorubicin)
Incubation Time: 48 h
Result: Increased apoptosis in KKU-100 cells in a dose-dependent manner, with the highest single-agent dose (2 μM) inducing ~32% apoptotic cells.
Induced ~75% apoptotic cells when combined with 0.025 μM Doxorubicin, which was significantly higher than either single agent alone.

Western Blot Analysis

Cell Line: human cholangiocarcinoma KKU-100 cells
Concentration: 0.25 μM; 0.5 μM; 1 μM (single agent); 0.25 μM + 0.006 μM Doxorubicin (C1); 0.5 μM + 0.012 μM Doxorubicin (C2); 1 μM + 0.025 μM Doxorubicin (C3)
Incubation Time: 48 h
Result: Decreased Bcl-2 expression (0.27-fold at 1 μM) and increased Bax expression (2.06-fold at 1 μM) as a single agent, leading to a Bax/Bcl-2 ratio of 1.63; the C3 combination further decreased Bcl-2 to 0.10-fold and increased Bax to 3.24-fold, resulting in a Bax/Bcl-2 ratio of 12.00.
Decreased survivin (0.35-fold at 1 μM), procaspase-9 (0.70-fold at 1 μM), and procaspase-3 (0.76-fold at 1 μM) while increasing activated caspase-9 (42.00-fold at 1 μM) and activated caspase-3 (42.00-fold at 1 μM) as a single agent; the C3 combination enhanced these effects, reducing procaspase-9 and procaspase-3 to 0-fold and increasing activated caspase-9 and caspase-3 to 64.00-fold and 54.00-fold, respectively.
Increased IκB-α (1.15-fold at 1 μM) and decreased pIκB-α (0.14-fold at 1 μM) and NF-κB/p65 (0.12-fold at 1 μM) as a single agent; the C3 combination further increased IκB-α to 1.21-fold and decreased pIκB-α and NF-κB/p65 to 0.01-fold each.
Decreased MRP1 expression (0.71-fold at 1 μM) as a single agent, while the C3 combination reduced MRP1 to 0.34-fold, a significantly greater effect than single-agent treatment.
体内研究
(In Vivo)
Animal Model: Syrian hamsters (male, 6-8 weeks old, intradermal injection of 2.5×105 Ham-1 cholangiocarcinoma cells)
Dosage: 50 mg/kg
Administration: p.o.; daily; 4 weeks
Result: Reduced tumor volume (P<0.01) and mean tumor weight from 0.54 g (control) to 0.27 g (P<0.001).
Significantly decreased relative CK19 mRNA expression in tumor tissues (P<0.05).
Significantly increased relative Bax, Apaf-1, caspase-9, and caspase-3 mRNA expression in tumor tissues (P<0.05).
Significantly decreased expression of CK19 (P=0.036), PCNA (P=0.032), cyclin A (P=0.028), and Bcl-2 (P=0.039) in tumor tissues via immunohistochemical analysis.
Significantly increased expression of Bax (P=0.039), caspase-9 (P=0.028), and caspase-3 (P=0.039) in tumor tissues via immunohistochemical analysis.
Increased body weight (P<0.001), food intake (P<0.001), and water intake (P<0.05) in treated hamsters.
Caused no significant histopathological changes in liver, kidney, or stomach, and no changes in serum liver (ALT, ALP) or kidney (BUN, creatinine) function markers.

化学信息

分子量 464.55
分子式 C28H32O6
CAS No. 667914-50-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础